Stock Track | Krystal Biotech Soars 5.99% Intraday on Strong Q4 Earnings Beat

Stock Track

Feb 17

Krystal Biotech Inc. (KRYS) stock soared 5.99% during intraday trading on Tuesday, reflecting a significant positive movement in the market.

The surge follows the company's release of its fourth quarter and full year 2025 financial results, which showed a strong earnings beat. Krystal Biotech reported Q4 EPS of $1.70, surpassing the FactSet consensus estimate of $1.54. The company's Q4 product revenue reached $107.1 million, driven by strong sales of its gene therapy VYJUVEK, representing a 74% increase year-on-year.

Further supporting investor optimism, the company maintained a robust cash position of $955.9 million and provided a positive outlook, including plans for the European launch of VYJUVEK and expansion of its global distributor network. Wall Street analysts maintain a "buy" rating on the stock with a median price target suggesting further upside.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1108872191"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108872191\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108872191?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108872191","market":"hk","top_or_hot":-1,"title":"Stock Track | Krystal Biotech Soars 5.99% Intraday on Strong Q4 Earnings Beat","media":"Stock Track","content":"<p>Krystal Biotech Inc. (KRYS) stock soared 5.99% during intraday trading on Tuesday, reflecting a significant positive movement in the market.</p><p>The surge follows the company's release of its fourth quarter and full year 2025 financial results, which showed a strong earnings beat. Krystal Biotech reported Q4 EPS of $1.70, surpassing the FactSet consensus estimate of $1.54. The company's Q4 product revenue reached $107.1 million, driven by strong sales of its gene therapy VYJUVEK, representing a 74% increase year-on-year.</p><p>Further supporting investor optimism, the company maintained a robust cash position of $955.9 million and provided a positive outlook, including plans for the European launch of VYJUVEK and expansion of its global distributor network. Wall Street analysts maintain a \"buy\" rating on the stock with a median price target suggesting further upside.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Krystal Biotech Soars 5.99% Intraday on Strong Q4 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Krystal Biotech Soars 5.99% Intraday on Strong Q4 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-17 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Krystal Biotech Inc. (KRYS) stock soared 5.99% during intraday trading on Tuesday, reflecting a significant positive movement in the market.</p><p>The surge follows the company's release of its fourth quarter and full year 2025 financial results, which showed a strong earnings beat. Krystal Biotech reported Q4 EPS of $1.70, surpassing the FactSet consensus estimate of $1.54. The company's Q4 product revenue reached $107.1 million, driven by strong sales of its gene therapy VYJUVEK, representing a 74% increase year-on-year.</p><p>Further supporting investor optimism, the company maintained a robust cash position of $955.9 million and provided a positive outlook, including plans for the European launch of VYJUVEK and expansion of its global distributor network. Wall Street analysts maintain a \"buy\" rating on the stock with a median price target suggesting further upside.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1108872191","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108872191","pubTimestamp":1771338835,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Krystal Biotech Inc. (KRYS) stock soared 5.99% during intraday trading on Tuesday, reflecting a significant positive movement in the market.The surge follows the company's release of its fourth...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"个股追踪|Krystal Biotech盘中飙升5.99%，因第四季度盈利强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"Krystal Biotech Inc. (KRYS) stock soared 5.99% during intraday trading on Tuesday, reflecting a significant positive movement in the market.The surge follows the company's release of its fourth quarter and full year 2025 financial results, which showed a strong earnings beat. Krystal Biotech reported Q4 EPS of $1.70, surpassing the FactSet consensus estimate of $1.54. The company's Q4 product revenue reached $107.1 million, driven by strong sales of its gene therapy VYJUVEK, representing a 74% increase year-on-year.Further supporting investor optimism, the company maintained a robust cash position of $955.9 million and provided a positive outlook, including plans for the European launch of VYJUVEK and expansion of its global distributor network. Wall Street analysts maintain a \"buy\" rating on the stock with a median price target suggesting further upside.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}